JANX014 for Advanced Prostate Cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a male, 18 years or older
- You have been diagnosed with prostate adenocarcinoma (a common type of prostate cancer)
- Your cancer has progressed despite previous hormone-blocking and chemotherapy treatments
- Your heart, liver, and kidneys are functioning adequately
- You have not had any prior CAR-T cell therapy, T-cell engager therapy, or radioligand therapy
- You do not have significant heart disease and have not had an organ transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
This trial tests two new investigational drugs, JANX013 and JANX007, together in men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination is safe and effective.
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
This trial tests BPX-601, a new type of cell therapy that uses your own immune cells to fight prostate cancer that has spread and stopped responding to hormone treatments. The study aims to see if this approach can help men whose cancer has returned despite multiple prior treatments.
This trial tests a new oral drug, XL092, for men with metastatic castration-resistant prostate cancer that has progressed after PSMA-targeted radiation therapy (Lu-177 PSMA-617). It aims to see if the drug can slow down the cancer.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.